𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting

✍ Scribed by Susumu Nakade; Tomoya Ohno; Junsaku Kitagawa; Yoshitaka Hashimoto; Masahiro Katayama; Hiroshi Awata; Yasuo Kodama; Yasuyuki Miyata

Publisher
Springer
Year
2008
Tongue
English
Weight
509 KB
Volume
63
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to

Randomized, placebo-controlled, pilot st
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
✍ Jon D. Herrington; Adam D. Jaskiewicz; Juhee Song 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract ## BACKGROUND. The combination of palonosetron and aprepitant is safe and effective in the prevention of chemotherapy‐induced emesis (CIE). The purpose of this pilot study was to ascertain the effectiveness of 1‐day versus 3‐day aprepitant in the prevention of acute and delayed nausea